CD276, also known as B7-H3, is an antigen highly expressed in several cancer types, including hepatocellular carcinoma (HCC, 79%-94% expression) and closely tied to aggressiveness and poor survival, but shows very low expression in normal tissues. Increasing evidence exists indicating B7-H3 has immune inhibitory functions, thus reducing interferon levels released by T cells and suppressing cytotoxic activity of natural killer cells, thereby aiding in tumor immune evasion.
Bispecific T-cell engagers (TCEs) aim to combat cancer by simultaneously binding T cells and tumor cells in order to induce the first to kill the second. This approach has failed to work effectively against many solid tumors because the exogenous engager proteins do not penetrate into tumors at sufficiently high concentrations.
Tahoe Therapeutics and Alloy Therapeutics Inc. are forming a jointly seeded new company focused on developing first-in-class antibody-drug conjugates (ADCs) for patients with hard-to-treat cancers. The joint venture will advance two ADC programs directed at novel tumor targets discovered by Tahoe using its proprietary Mosaic platform and large-scale, perturbative single-cell datasets.
Dentatorubral-pallidoluysian atrophy (DRPLA) is a lethal neurodegenerative disorder caused by pathogenic expansion of CAG repeats within the atrophin-1 (ATN1) gene. As DRPLA belongs to the broader class of repeat expansion disorders (RED) that are driven by toxic gain-of-function effects, reduction or elimination of ATN1 expression is predicted to provide therapeutic benefit.
The colchicine-binding domain (CBD) of tubulin, one of the earliest identified regulatory sites, remains underexplored in oncology despite its proven success in other therapeutic areas. Drugs targeting CBD are widely used for gout, parasitic infections or actinic keratosis. However, no CBD-directed agents have reached clinical use for cancer, highlighting a significant opportunity to exploit this domain for novel anticancer strategies.
Généthon, a nonprofit laboratory created by the AFM-Téléthon, has reported its exclusive, worldwide licensing agreement with Askbio Inc., a subsidiary of Bayer AG, for the use of a patented component of AB-1009, under development by Askbio, for the treatment of Pompe disease.
Animate Biosciences Inc. has released promising preclinical results from a mouse model of pulmonary fibrosis demonstrating that two of its AI-designed therapeutic peptides significantly reduced lung fibrosis and inflammation.
Asthma is an inflammatory airway disease characterized by shortness of breath and wheezing, among others, with a varying global prevalence of 1%-18%. Both airway hyperresponsiveness and airway remodeling are two important features of the disease, where epithelial-mesenchymal transition (EMT) plays a critical role. Glucocorticoid induced 1 (GLCCI1) is a protein involved in glucocorticoid signaling that has gained interest in the field of asthma, where it has been shown to be downregulated in the lung tissues of mice with asthma and its overexpression has been found to alleviate airway remodeling.
Hainan Simcere Pharmaceutical Co. Ltd. has described N-myristoyltransferase 1 (NMT1) and NMT2 inhibitors reported to be useful for the treatment of cancer.
RSS
